HealthCare Institute of New Jersey Statement on Second Round of IRA Price Controls

Trenton, January 17, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the second round of government-imposed price controls on life-saving medicines announced by the Department of Health and Human Services. “There are smart and efficient ways to lower health care costs with […]

HealthCare Institute of New Jersey Statement on the FTC Report on PBMs

Trenton, January 15, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning yesterday’s second report issued by the Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs), which found they charge significant markups for medicines treating serious conditions including cancer, multiple sclerosis, HIV, […]

HealthCare Institute of New Jersey and Organon Held “Advancing Women’s Health” Forum, Featuring First Lady Tammy Murphy, Congresswoman Bonnie Watson Coleman and Department of Human Services Commissioner Sarah Adelman

Trenton, December 17, 2024 ― The HealthCare Institute of New Jersey and Organon (www.organon.com), with premier sponsor Novartis and supporting sponsor Ferring, hosted a forum on December 16 titled “Advancing Women’s Health” – a half-day seminar highlighting New Jersey’s life sciences’ commitment to women’s health and innovating new medical advances and treatments for women.  Read […]

Op-Ed: Protect Future Cures While Lowering Cost of Health Care

An op-ed by Chrissy Buteas, HINJ President and Chief Executive Officer. New Prescription Drug Affordability Council must take a balanced approach that helps patients without harming potential cures The cost of health care is a critical issue — for patients, for families and loved ones, and for businesses and governments. It can often mean the […]

HealthCare Institute of New Jersey Statement on the Senate Legislative Oversight Committee’s AI Hearing

Trenton, October 21, 2024 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning today’s Senate Legislative Oversight Committee Hearing entitled, “How artificial intelligence (AI) is defined and the AI landscape in New Jersey.” “New Jersey and our state’s innovation ecosystem are at the forefront […]

HealthCare Institute of New Jersey Statement on the Prescription Drug Affordability Council

Trenton, October 11, 2024 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the State’s recent completion of appointments to the Prescription Drug Affordability Council (PDAC): “Drug development is an extraordinarily complex and multifaceted journey, with middlemen in the supply chain – such as […]